Tazerestat inhibits EZH2 enzyme

Tazerestat is a high-profile targeted drug. Its core mechanism of action focuses on the precise inhibition of EZH2 (i.e. enhancer homeobox 2) enzyme. EZH2, as a key histone methyltransferase, plays an important role in regulating gene expression. It achieves this function by methylating lysine at position 27 of histone H3.

In a normal cellular environment, EZH2 activity is finely regulated to maintain a delicate balance of gene expression. However, in various cancers, the expression or activity of EZH2 is abnormally increased, leading to excessive methylation of the gene, thereby silencing some key tumor suppressor genes, providing favorable conditions for the proliferation and survival of cancer cells.

Tazetostat was developed to target this cancer-driving mechanism. It can bind tightly to the catalytic site of EZH2, effectively preventing EZH2’s methylation of H3K27, thereby breaking EZH2-mediated gene silencing, allowing the silenced genes to be re-expressed. This mechanism of action helps break the abnormal growth control of cancer cells and provides a new way to inhibit cancer progression.

In clinical practice, this mechanism of action of tazerestat is particularly applicable to cancer types where theEZH2 gene is mutated or overexpressed, such as epithelioid sarcoma and certain follicular lymphomas. These cancer types often rely on the abnormal activity of EZH2 to maintain their malignant characteristics. Therefore, tazerestat can effectively interfere with the growth and survival of cancer cells by inhibiting EZH2.

To sum up, tazerestat, with its unique mechanism of targeting the EZH2 enzyme, has opened up a new way to treat specific types of cancer and brought new treatment hope to patients.